97,889 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Bought by Velan Capital Investment Management LP

Velan Capital Investment Management LP purchased a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 97,889 shares of the company's stock, valued at approximately $1,844,000. Nurix Therapeutics accounts for approximately 1.6% of Velan Capital Investment Management LP's investment portfolio, making the stock its 13th largest position. Velan Capital Investment Management LP owned 0.13% of Nurix Therapeutics as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. FMR LLC lifted its position in shares of Nurix Therapeutics by 1,711.9% in the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock valued at $200,349,000 after acquiring an additional 10,047,329 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Nurix Therapeutics by 8.3% in the fourth quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after acquiring an additional 333,452 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Nurix Therapeutics by 3.0% in the fourth quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock valued at $67,572,000 after acquiring an additional 104,500 shares in the last quarter. Soleus Capital Management L.P. lifted its position in shares of Nurix Therapeutics by 97.3% in the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock valued at $39,617,000 after acquiring an additional 1,036,999 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Nurix Therapeutics by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock valued at $29,870,000 after acquiring an additional 137,087 shares in the last quarter.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock traded down $0.27 during mid-day trading on Friday, reaching $9.72. 401,505 shares of the company were exchanged, compared to its average volume of 871,857. The business has a fifty day moving average of $10.67 and a 200 day moving average of $16.39. The firm has a market cap of $741.01 million, a P/E ratio of -3.36 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The company had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the prior year, the business earned ($0.76) earnings per share. Sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Morgan Stanley boosted their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a research report on Monday, February 3rd. Leerink Partners assumed coverage on Nurix Therapeutics in a research report on Monday, March 17th. They issued a "market perform" rating and a $16.00 target price on the stock. Royal Bank of Canada boosted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. Finally, Wells Fargo & Company decreased their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $30.44.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 6,198 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company's stock, valued at $382,092.92. This trade represents a 15.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider now directly owns 61,516 shares of the company's stock, valued at $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,838 shares of company stock worth $221,500 over the last 90 days. Company insiders own 7.40% of the company's stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.